Last reviewed · How we verify
Kanecia Obie Zimmerman — Portfolio Competitive Intelligence Brief
2 marketed
0 filed
0 Phase 3
4 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| 0.25% Timolol Maleate Gel Forming Solution | 0.25% Timolol Maleate Gel Forming Solution | marketed | ||||
| 0.5% Timolol Maleate Gel Forming Solution | 0.5% Timolol Maleate Gel Forming Solution | marketed |
Therapeutic area mix
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
Subscribe to ongoing alerts
Every new pipeline event for Kanecia Obie Zimmerman:
- Kanecia Obie Zimmerman pipeline updates — RSS
- Kanecia Obie Zimmerman pipeline updates — Atom
- Kanecia Obie Zimmerman pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Kanecia Obie Zimmerman — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/kanecia-obie-zimmerman. Accessed 2026-05-16.